Badger Meter vs Cognex
BMI and CGNX side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMI and CGNX compare
Cognex is the larger company, worth 1.9 times as much as Badger Meter ($8.5B against $4.4B).
On earnings, Badger Meter is cheaper: it trades at 32.1× trailing earnings, against 35.5× for Cognex.
Cognex grew revenue faster over the last twelve months (15.8% versus 10.9% for Badger Meter).
Cognex keeps more of each dollar of sales as profit, with a net margin of 21.5% compared with 15.5% at Badger Meter.
Both pay dividends: Badger Meter yields 1.1% and Cognex 0.67%.
Badger Meter scores higher on the StockData Score (25 against 19 for Cognex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMI | CGNX |
|---|---|---|
| Size and price | ||
| Market cap | $4.4B | $8.5B |
| Share price | $153.59 | $50.77 |
| Change, 1 year | −17.2% | 32.2% |
| Change, 5 years | 41.7% | −36.5% |
| Beta (5Y) | 0.82 | 1.30 |
| Employees | 2,477 | 2,267 |
| StockData Score | ||
| Total score | 25 (better) | 19 |
| Valuation score | 5 (better) | 3 |
| Growth score | 4 (better) | 3 |
| Performance score | 6 (better) | 4 |
| Health score | 6 | 6 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 32.1× (better) | 35.5× |
| P/S | 4.8× (better) | 7.6× |
| P/B | 6.7× | 5.0× (better) |
| EV/EBITDA | 23.5× (better) | 27.9× |
| P/FCF | 25.9× (better) | 29.9× |
| PEG | 1.13 | – |
| FCF yield | 3.9% (better) | 3.3% |
| Fair value | $194.99 | $57.31 |
| Margin of safety | 21.2% (better) | 11.4% |
| Growth | ||
| Revenue growth (TTM) | 10.9% | 15.8% (better) |
| Revenue growth, 5Y average | 16.6% (better) | 4.2% |
| Net income growth (TTM) | 13.4% | 120% (better) |
| EPS growth (TTM) | 13.2% | 123% (better) |
| EPS growth, 5Y average | 23.2% (better) | −7.4% |
| Profitability | ||
| Gross margin | 41.7% | 69.7% (better) |
| Operating margin | 20.0% | 25.0% (better) |
| Net margin | 15.5% | 21.5% (better) |
| FCF margin | 18.5% | 25.4% (better) |
| Return on equity | 22.5% (better) | 15.1% |
| Return on invested capital | 30.8% (better) | 20.6% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.48 | 5.04 (better) |
| Altman Z-score | 11.93 (better) | 10.91 |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.1% (better) | 0.67% |
| Payout ratio | 30.7% | 23.5% |
| Years of dividend growth | 11 (better) | 4 |
| Dividend growth, 5Y average | 16.2% (better) | −31.9% |
| Buyback yield | 0.34% | 1.5% (better) |
| Shareholder yield | 1.4% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 114% | 104% |
| Held by insiders | 0.68% | 0.38% |
| Insider net buying, 12 months | $1.5M (better) | −$34.8M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 13.5% | 3.9% |
Go deeper
- BMI stock overview
- BMI income statement
- BMI valuation and score
- CGNX stock overview
- CGNX income statement
- CGNX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.